Palivizumab, A Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection In High-risk Infants

·1998·DOI

Role in the Field

Abstract

Citations

1,655

Year

1998

PageRank

3.9 / 10

Relative influence (log-scaled)

Palivizumab, A Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection In High-risk Infants | Manumap